AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab solutions. This app...

Finance Minister Nirmala Sitharaman presented the Union Budget 2025, highlighting measures to enhance healthcare affordability. Key initiat...

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and 150mg doses. Th...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed drug manufacturer...

The government has directed manufacturers to lower prices of Trastuzumab, Osimertinib, and Durvalumab after exempting them from customs dut...

AstraZeneca Pharma Share Price: The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple ...

Stocks in news: Domestic markets started the week positively, gaining nearly half a percent. Key stocks in focus include Reliance Power, Co...

Drugs made locally, be it under patent or generic, must be of high and uniform quality. Variations in quality has dogged the domestic pharm...

The Union Budget 2024, while significantly increasing health sector funding to ₹90,959 crore, failed to address the BJP’s poll promise of i...

Shea butter cosmetics — customs duty on shea nuts reduced to 15% from 30%. Stretchable clothes that contain spandex, such as jeans and tops...

Union Budget 2024 benefits pharma, healthcare by exempting AstraZeneca's cancer drugs Trastuzumab Deruxtecan, Osimertinib, Durvalumab, boos...

The Union health ministry receives a budget increase to Rs 90,958.63 crore for 2024-25. Customs duty exemptions on three cancer drugs annou...

The government proposes to cut custom duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil. Finance Ministe...

British-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, re...

The primary endpoint was overall survival (OS) for the combination versus sorafenib and secondary endpoints included OS for durvalumab vers...

Drug firm AstraZeneca India on Friday said it has received approval from the domestic drug regulator to market a drug to treat biliary trac...

Shares of AstraZeneca Pharma climbed as much as 4.72 per cent in the early trade.